Quarterly report [Sections 13 or 15(d)]

Significant Agreements (Details)

v3.25.1
Significant Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 10, 2023
Feb. 01, 2023
Dec. 31, 2022
Jul. 14, 2022
Jan. 06, 2022
Sep. 30, 2021
Jul. 13, 2021
Sep. 30, 2018
Oct. 31, 2017
Mar. 31, 2025
Mar. 31, 2024
Sep. 30, 2021
Dec. 31, 2024
Feb. 28, 2023
Aug. 31, 2022
Significant Agreements [Line Items]                              
Agreement due payments                 $ 1,650,000            
Second clinical trial payment                 $ 50,000            
Royalty percentage                 2.00%            
Common stock valued                   $ 2,706,000          
Anti-dilution shares of common stock (in Shares)                   102,184,967 176,062,865        
Revision overall budget         $ 2,900,000                    
Related payments                   $ 2,800,000          
Research related payments $ 2,900,000                            
Milestone payments   $ 3,700,000                          
Payment amount                         $ 6,500,000    
Exclusive license agreement [Member]                              
Significant Agreements [Line Items]                              
Agreement due payments                 $ 50,000            
Spectrum Agreement [Member]                              
Significant Agreements [Line Items]                              
Issued of common shares (in Shares)               313,663              
Common stock valued               $ 4,000              
Public market capitalization             $ 50,000,000 $ 50,000,000              
Research and development expenses                       $ 2,200,000      
Sub license income granted percentage           40.00%                  
Sublicense income percentage     20.00%                 20.00%      
Spectrum Agreement [Member] | Investment [Member]                              
Significant Agreements [Line Items]                              
Interest on ownership               4.00%              
Spectrum Agreement [Member] | Common Stock [Member]                              
Significant Agreements [Line Items]                              
Anti-dilution shares of common stock (in Shares)             438,374                
Sublicense Development Agreement [Member]                              
Significant Agreements [Line Items]                              
Significant payment received                           $ 700,000 $ 1,000,000
Lotus International Pte Ltd [Member]                              
Significant Agreements [Line Items]                              
Sublicense income percentage                   20.00%          
Quotient Sciences Limited [Member]                              
Significant Agreements [Line Items]                              
Research and development expenses         $ 3,700,000                    
Altair Nanomaterials, Inc [Member] | Spectrum Agreement [Member]                              
Significant Agreements [Line Items]                              
Required to pay                       $ 200,000      
Altair [Member] | Spectrum Agreement [Member]                              
Significant Agreements [Line Items]                              
Required to pay                       $ 4,500,000      
Quotient Sciences Limited [Member]                              
Significant Agreements [Line Items]                              
Research related payments                   $ 2,800,000     2,800,000    
Inotiv [Member]                              
Significant Agreements [Line Items]                              
Payments to related party                   $ 2,900,000          
Lee’s Pharmaceutical (HK) Limited [Member]                              
Significant Agreements [Line Items]                              
Significant payment received       $ 1,000,000                      
Milestone payments       $ 1,000,000                      
Lotus International Pte Ltd [Member]                              
Significant Agreements [Line Items]                              
Significant payment received   $ 700,000                          
Shilpa Medicare Ltd [Member]                              
Significant Agreements [Line Items]                              
Payment amount                         $ 6,500,000    
Minimum [Member]                              
Significant Agreements [Line Items]                              
Royalties percentage       7.00%                      
Maximum [Member]                              
Significant Agreements [Line Items]                              
Royalties percentage       10.00%